Veracyte (VCYT) Total Non-Current Liabilities (2012 - 2026)
Veracyte (VCYT) posted quarterly Total Non-Current Liabilities of $97.0 million for Q2 2026, down 20.77% year-over-year from $122.5 million in Q2 2025, and up 6.93% on a QoQ basis from $90.8 million in Q1 2026.
Veracyte (VCYT) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Veracyte has reported Total Non-Current Liabilities for 11 years, with the latest figure at $97.0 million in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $97.0 million, down 20.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $97.0 million (down 20.77% YoY), and the FY2025 annual result was $94.9 million, down 23.2% from the prior year.
- Total Non-Current Liabilities improved to $97.0 million in Q2 2026, from $90.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $123.5 million in Q4 2024 and troughed at $68.0 million in Q1 2024.
- A 5-year average of $89.4 million and a median of $83.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2024, when Total Non-Current Liabilities jumped 76.39%; it then fell 24.31% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $78.7 million in 2022, then fell by 11.06% to $70.0 million in 2023, then jumped by 76.39% to $123.5 million in 2024, then declined by 23.2% to $94.9 million in 2025, then gained by 2.31% to $97.0 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $97.0 million in Q2 2026, $90.8 million in Q1 2026, and $94.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 108.64 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 85.84 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 542.10 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 5.45 Bn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 22.94 Bn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 737.18 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 6.36 Bn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 3.39 Bn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.88 Bn |
| 10 | Veracyte | 3.69 Bn | 3.39 Bn | 108.55 Mn | 97.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.04 Mn |
| Mar 31, 2026 | 90.76 Mn |
| Dec 31, 2025 | 96.19 Mn |
| Sep 30, 2025 | 110.12 Mn |
| Jun 30, 2025 | 122.47 Mn |
| Mar 31, 2025 | 120.03 Mn |
| Dec 31, 2024 | 123.66 Mn |
| Sep 30, 2024 | 84.75 Mn |
| Jun 30, 2024 | 99.60 Mn |
| Mar 31, 2024 | 67.98 Mn |
| Dec 31, 2023 | 70.29 Mn |
| Sep 30, 2023 | 70.11 Mn |
| Jun 30, 2023 | 73.54 Mn |
| Mar 31, 2023 | 75.07 Mn |
| Dec 31, 2022 | 80.29 Mn |
| Sep 30, 2022 | 76.63 Mn |
| Jun 30, 2022 | 77.69 Mn |
| Mar 31, 2022 | 82.67 Mn |
| Dec 31, 2021 | 89.90 Mn |
| Sep 30, 2021 | 77.39 Mn |